NASDAQ$OM
Outset Medical Inc · Q1 2026 earnings
Q1 2026 earnings · · After market close · Investor relations
Briefing
Outset Medical reported Q1 2026 revenue of $27.9M and a net loss of $19.0M, with diluted loss per share of $1.03.
Total revenue was $27.9 million (-6% YoY) for the Tablo dialysis system maker. Net loss was $19.0 million vs. $25.8 million; diluted loss per share was $1.03. R&D and sales and marketing remained the largest operating costs.
- Revenue $27.9M (-6% YoY).
- Net loss $(19.0)M; diluted EPS $(1.03).
- Product and service revenue mix.
- Interest expense and debt overhang.
Headline financials
Revenue & EPS history
Outset Medical · Revenue · Quarterly
$27.9M
Revenue by segment
Outset Medical · $30.4M total across 2 segments · Q3 2023
- Product Revenue$23.5M—77.5%
- Service and Other Revenue$6.83M—22.5%
Forward guidance
Tablo adoption and home dialysis penetration are MD&A themes.
Tailwinds
- Loss narrowed vs. prior year.
- Differentiated dialysis technology.
Headwinds
- Revenue decline.
- Path to profitability still uncertain.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2026
-2.7%
Avg return
Earnings day
-4.8%
Avg return
5 days after
+0.5%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+33.5%
Q1 2025
Best reaction
-69.6%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.2% | -17.1% | -2.3% | |
| Q4 2025 | -16.3% | -28.4% | -28.3% | |
| Q3 2025 | -48.6% | -61.2% | -64.5% | |
| Q1 2025 | +33.5% | +46.8% | +78.3% | |
| Q4 2024 | +2.1% | -13.0% | -28.7% | |
| Q3 2024 | +23.7% | +36.0% | +91.4% | |
| Q2 2024 | -69.6% | -75.0% | -86.1% | |
| Q1 2024 | -13.7% | -18.2% | +18.7% | |
| Q4 2023 | +1.8% | +9.3% | -40.6% | |
| Q3 2023 | -13.6% | -13.8% | +33.7% | |
| Q2 2023 | -14.6% | -17.5% | -31.8% | |
| Q1 2023 | +8.3% | +3.4% | +15.4% | |
| Q4 2022 | -6.5% | -10.6% | -30.5% | |
| Q3 2022 | +20.2% | +44.2% | +82.5% | |
| Q2 2022 | +21.8% | +23.5% | +18.4% | |
| Q1 2022 | -13.2% | -38.5% | -39.5% | |
| Q4 2021 | +9.5% | +15.9% | +22.6% | |
| Q3 2021 | -0.1% | -4.6% | -22.9% | |
| Q2 2021 | -2.5% | -9.9% | +21.1% | |
| Q1 2020 | -5.6% | -14.4% | -16.7% | |
| Q1 2021 | -9.1% | -11.9% | -17.6% | |
| Q2 2020 | +6.0% | +0.1% | +12.2% | |
| Q4 2020 | +12.5% | +8.9% | +18.4% | |
| Q3 2020 | +5.5% | +29.6% | +8.4% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro